|
Time |
Source |
|
Announcement
|
|
31 Jul 2018 |
7:00 am |
GNW
|
|
|
TiGenix (0EIT) |
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period |
23 Jul 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
06 Jul 2018 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid |
02 Jul 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency Information |
27 Jun 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
22 Jun 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
19 Jun 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
14 Jun 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
13 Jun 2018 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix announces a change in its Board of Directors and its Management Team |
06 Jun 2018 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period |
28 May 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
14 May 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
08 May 2018 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 7 JUNE 2018 |
13 Apr 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
12 Apr 2018 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix reports 2017 full year results |
10 Apr 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
30 Mar 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
23 Mar 2018 |
5:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval to treat complex perianal fistulas in Crohn's disease in Europe |
06 Feb 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency Information |
31 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
26 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix:Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
19 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency Information |
18 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
16 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
15 Jan 2018 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601 |
12 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
Transparency notifications pursuant to Article 14 of the Law of May 2, 2007 |
11 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: Transparency Information |
05 Jan 2018 |
6:30 am |
GNW
|
|
|
TiGenix (0EIT) |
Takeda announces its intention to acquire TiGenix |
03 Jan 2018 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
Transparency notification pursuant to Article 14 of the Law of May 2, 2007 |
20 Dec 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix confirms strategic focus on Cx601 and its adipose derived stem cell (eASC) platform |
15 Dec 2017 |
12:11 pm |
GNW
|
|
|
TiGenix (0EIT) |
Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn's disease |
14 Dec 2017 |
11:21 pm |
GNW
|
|
|
TiGenix (0EIT) |
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae |
24 Nov 2017 |
9:00 pm |
GNW
|
|
|
TiGenix (0EIT) |
JPMorgan Chase & Co notifies 3.12% shareholding in TiGenix |
20 Nov 2017 |
8:31 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting |
16 Nov 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix announces approval of trade name for lead development candidate Cx601 in Europe |
06 Nov 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix announces partial conversion of bonds |
02 Nov 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix strengthens European IP protection around lead development program Cx601 |
31 Oct 2017 |
6:01 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure |
23 Oct 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix granted Orphan Drug Designation from the U.S. FDA for Cx601 |
05 Oct 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to present positive 52-week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meeting |
02 Oct 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to host Analyst and Investor Event in New York City |
28 Sep 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to participate and present at key investor and business development meetings |
19 Sep 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix Business and Financial Update for the First Half 2017 |
12 Sep 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix strengthens US operations with senior appointments |
05 Sep 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix obtains commercial production license for expanded manufacturing facility |
23 Jun 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to present at the 7th TERMIS-EU Conference in Davos, Switzerland |
20 Jun 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
Takeda and TiGenix announce that Swissmedic has accepted for review the file on Cx601 for the treatment of complex perianal fistulas in Crohn's disease patients |
15 Jun 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix Partners with U.S. and European Patient Advocacy Groups Focused on Crohn's Disease and Ulcerative Colitis |
13 Jun 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix Launches Global Phase III Trial for Cx601 |
12 Jun 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix announces final equity payment for cardiac platform acquisition |
01 Jun 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to present at the Jefferies 2017 Global Healthcare Conference in New York |
31 May 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix provides regulatory update on Cx601 EU Marketing Authorization Application procedure |
11 May 2017 |
6:03 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to present at Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas |
10 May 2017 |
6:02 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to present at the Crohn's and Colitis Foundation's Novel Technologies in Inflammatory Bowel Disease workshop in New York |
04 May 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix Cx601 positive long-term results to be presented at Digestive Disease Week |
02 May 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix: CONVENING NOTICE TO THE ANNUAL SHAREHOLDERS' MEETING TO BE HELD ON 1 JUNE 2017 |
06 Apr 2017 |
6:01 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix reports 2016 full year results |
05 Apr 2017 |
6:01 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix to participate in key investor conferences in April 2017 |
13 Mar 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction |
09 Mar 2017 |
6:00 am |
GNW
|
|
|
TiGenix (0EIT) |
TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial |